Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients

Summary

Low bone mineral density (BMD) is commonly reported in patients receiving home parenteral nutrition (HPN). Denosumab represent a new drug, which helped to prevent osteoclast. The aim of the study was to assess its value in chronic intestinal failure patients.

Timeline

Start

2011-01

Primary completion

2016-07

Completion

2016-07

Drugs

Indications